Table 1.

Patient information

Histology	Previous treatment	Checkpoint inhibitor	Special finding	Onset after start of immunotherapy	Clinical findings	Imaging	Treatment
Adenocarcinoma	S, CHT	Nivolumab	Pseudoprogression	4 weeks	Unremarkable	>20% increase SLD	N/A
Adenocarcinoma	CHT, RT	Durvalumab	Pseudoprogression	4 weeks	Unremarkable	New bone mass	N/A
Adenocarcinoma	CHT	Nivolumab	Sarcoid-like reaction	4 weeks	Dyspnea—due do pleural effusion	Pulmonary micronodule in perilymphatic distribution; mediastinal lymphadenopathy	N/A
Adenocarcinoma	CHT	Atezolizumab	Pneumonitis	4 weeks	Increasing dyspnea	Ground-glass opacities and consolidation, mediastinal lymphadenopathy	Cortisone; pause atezolizumab
Adenocarcinoma	CHT, RT	Durvalumab	Pneumonitis	11 weeks	Worsening general condition	Ground-glass opacities	Cortisone; pause durvalumab

S surgery, CHT cytotoxic chemotherapy, RT radiotherapy, SLD sum of the longest diameters, N/A not applicable